3Esbfit P, Hurtado J. Treatment of malignant hypercalcaemia [ J ]. Expert OpinPharmacother, 2002 ;3 (5) :521 - 527.
4Campagnuolo G, Bolon B, Feige U. Kinetics of bone protection by recombinant osteoprotegefin therapy in Lewis rats with adjuvant arthritis [ J ]. Arthritis Rheum, 2002 ;46(7) :1926 - 1936.
5Goater J J, O'Keefe R J, Rosier RN et al.Efficacy of ex vivo OPG gene therapy inpreventing wear debris induced osteolysis[J]. J Orthop Res, 2002;20(2):169 -173.
6Grigoriadis AE, Wang ZQ, Cecchini MG et al. c-Fos: a key regulator of osteoclastmacrophage lineage determination and bone remodeling [ J ]. Science, 1994; 266(5184) :443 -448.
7Soriano P, Montgomery C, C, eske R et al.Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice [ J ].Cell, 1991 ;64(4) :693 -702.
8Fuller K, Wong B, Fox Set al. TRANCE is necessary and suffient for osteoblast-mediated activation of bone resorption in osteoclasts[J]. J Exp Med,1998;188(5) :997- 1001.
9Kong YY, Yoshida H, Sarosi 1 et al. OPGL is key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis [ J ]. Nature, 1999 ; 397 ( 6717 ) :315 -323.
10Bucay N, Sarosi 1, Dunstan CR et al. Osteoprotegefin-deficient mice develop early onset osteoporosis and arterial calcification[J]- Genes Dev, 1998;12(9):1260 -1268.
二级参考文献11
1WickelgrenI. Science . 1 999
2TsudaE,GotoM,MochizukiS ,etal. Biochemical and Biophysical Research Communications . 1 997
3TomoyasuA,GotoM,FujiseN ,etal. Biochemical and Biophysical Research Communications . 1 998
4KongYY,FeigeU,SarosiI,etal. Nature . 1 999
5HofbauerLC,HeufelderAE. EurJEndocrinol . 1 998
6JimiE,AkiyamaS,TsurukaiT ,etal. JImmunol . 1 999
7GreenfieldEM,BiY,MiyauchiA. Life Sciences . 1 999
8UdagawaN,TakahashiN,JimiE ,etal. Bone . 1 999
9MakhlufHA,MuellerSM,MizunoS ,etal. Biochemical and Biophysical Research Communications . 2 0 0 0
